MetLife stock downgraded by Piper Sandler as shares near fair value

Piper Sandler downgraded MetLife (MET) to Neutral with an $84.00 price target, citing the stock's proximity to fair value and concerns over increased competition in institutional spread manufacturing due to potential lower interest rates and capital inflows. This re-rating follows MetLife's Q2 2025 adjusted earnings of $2.20 per share, a 16% decrease year-over-year, and revenue of $17.92 billion, both missing analyst expectations. The downgrade, alongside other analyst price target reductions and a warning about an unsolicited mini-tender offer, signals growing headwinds for the insurer despite some metrics indicating strong underlying financial health.

Analysis

Piper Sandler's downgrade of MetLife (MET) to Neutral from Overweight, while maintaining an $84 price target, signals a belief that the stock is approaching fair value and that positive catalysts are now fully priced in. The rationale is twofold: known catalysts such as the Chariot Re capabilities and the MetLife Investment Management breakout are already understood by the market, and forward-looking headwinds are emerging. Specifically, Piper Sandler expresses concern that a potential decline in interest rates will heighten competition in the institutional spread manufacturing business, compressing margins as more capital from alternative asset managers enters the space. This analyst action is contextualized by MetLife's recent weak performance, including a Q2 2025 revenue of $17.92 billion that missed forecasts by 3.4% and adjusted earnings of $2.20 per share, which represented a 16% year-over-year decline. This sentiment is echoed by other firms, with BMO Capital lowering its price target to $82 due to revised forward EPS estimates and Evercore ISI trimming its target to $108, citing mixed results. Despite these headwinds, some metrics like a perfect Piotroski Score of 9 suggest strong underlying financial health, creating a conflicting picture for investors to navigate.

Key Decisions for Investors

• Given that multiple analysts have trimmed price targets and view key catalysts as already priced-in, investors should re-evaluate the near-term upside as the stock approaches the consensus fair value range around $82-$84.
• Monitor future interest rate movements and company commentary on competitive pressures within the institutional spread business, as this is highlighted as a primary forward-looking risk to margin and profitability.
• Scrutinize upcoming earnings reports for evidence of fundamental stabilization, paying close attention to revenue growth and the performance of the group benefits segment following the recent top-and-bottom-line miss in Q2 2025.